Sorafenib, an antineoplastic medication approved by the U.S. Food and Drug Administration (FDA) for advanced thyroid cancer, inhibits receptor tyrosine kinases, acting on receptors of angiogenic factors [39]. This evidence concerns the gene NTRK1 and thyroid gland carcinoma.